Replies to post #384 on Equity Field Notes from temporal sources

[DanWebzster]

AFMD is a pioneer in directing the innate immune system to fight cancer

It's lead assett, AFM13 has been significantly de-risked in 2020 with a successful POC study.

It has 3 clinical stage programs, each with a potential milestone during the remainder of 2020:

1. Although AFM13 addresses a target for which SGEN is already marketing an approved drug. AFM13 is thought to be significantly less toxic. More interim data is expected this year.

2. Initial clinical AFM24 data will likely be presented this H2 2020. In principle, every cancer patient overexpressing EGFR is a potential user of this drug.

3. Genentech may report progress on the Multiple Myeloma program they licensed from AFMD.

With some of the resources from their lucrative deal with Genentech, AFMD hired a COO from Sandoz.

Cash runway extends into 2022

[DanWebzster]

BCRX has 3 important milestones remaining in 2020:

1) Preliminary Galdesivir Ph I data of wuflu patients in Brazil
2) Additional Ph I dose escalation results in both PNH treatment
naive and PNH patients taking CS inhibitors
3) 12/3 PDUFA

Galdesivir has worked in animal studies against other RNA viruses including Ebola, Marburg, Yellow Fever and Zika

BCX9030 data in PNH (Paroxysmal Nocturnal Hemoglobinuria) is due Q3/2020. This indication is a competitive space (ALXN , APLS); but, relative success in PNH could be a gateway to larger complement indications such as C3 glomerulopathy.

BCRX raised 140M 5/20 to bring cash to 225M EOQ1/20.

Cash burn for 2020 is estimated to be 125-150M

Cash runway thru mid 2021.

Assuming Berotralstat approval, at least one more cap raise will be necessary to bring BCRX to break even.